Sneha Mitra

Sneha Mitra

Auto-generated profile, based on publicly available information

Sneha Mitra

Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York City, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2024 in Nature Genetics
Verified
Journal Article
Open access
PDF file
SMSneha Mitra
Sneha Mitra
RMRohan Malik
Rohan Malik
WWWilfred Wong
Wilfred Wong
ARAfsana Rahman
Afsana Rahman
AHAlexander J. Hartemink
Alexander J. Hartemink
CLChristina S. Leslie
Christina S. Leslie
We present a gene-level regulatory model, single-cell ATAC + RNA linking (SCARlink), which predicts single-cell gene expression and links enhancers to target genes using multi-ome (scRNA-seq and scATAC–seq co-assay) sequencing data. The approach uses regularized Poisson regression on tile-level accessibility data to jointly model all regulatory effects at a gene locus, avoiding the limitations of pairwise gene–peak correlations and dependence on peak calling. SCARlink outperformed existing gene scoring methods for imputing gene expression from chromatin accessibility across high-coverage multi-ome datasets while giving comparable to improved performance on low-coverage datasets. Shapley value analysis on trained models identified cell-type-specific gene enhancers that are validated by promoter capture Hi-C and are 11× to 15× and 5× to 12× enriched in fine-mapped eQTLs and fine-mapped genome-wide association study (GWAS) variants, respectively. We further show that SCARlink-predicted and observed gene expression vectors provide a robust way to compute a chromatin potential vector field to enable developmental trajectory analysis.

13 July 2021 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
SMSneha Mitra
Sneha Mitra
JZJianling Zhong
Jianling Zhong
TTTrung Q Tran
Trung Q Tran
DMDavid M. MacAlpine
David M. MacAlpine
AHAlexander J. Hartemink
Alexander J. Hartemink
Chromatin is a tightly packaged structure of DNA and protein within the nucleus of a cell. The arrangement of different protein complexes along the DNA modulates and is modulated by gene expression. Measuring the binding locations and occupancy levels of different transcription factors (TFs) and nucleosomes is therefore crucial to understanding gene regulation. Antibody-based methods for assaying chromatin occupancy are capable of identifying the binding sites of specific DNA binding factors, but only one factor at a time. In contrast, epigenomic accessibility data like MNase-seq, DNase-seq, and ATAC-seq provide insight into the chromatin landscape of all factors bound along the genome, but with little insight into the identities of those factors. Here, we present RoboCOP, a multivariate state space model that integrates chromatin accessibility data with nucleotide sequence to jointly compute genome-wide probabilistic scores of nucleosome and TF occupancy, for hundreds of different factors. We apply RoboCOP to MNase-seq and ATAC-seq data to elucidate the protein-binding landscape of nucleosomes and 150 TFs across the yeast genome, and show that our model makes better predictions than existing methods. We also compute a chromatin occupancy profile of the yeast genome under cadmium stress, revealing chromatin dynamics associated with transcriptional regulation.

4 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
HEHarold K. Elias
Harold K. Elias
SMSneha Mitra
Sneha Mitra
MSMarina B. da Silva
Marina B. da Silva
ARAdhithi Rajagopalan
Adhithi Rajagopalan
BGBrianna Gipson
Brianna Gipson
MBMarcel R. M. van Den Brink
Marcel R. M. van Den Brink
Hematopoietic stem cells (HSC) with multilineage potential are critical for T cell reconstitution after allogeneic hematopoietic cell transplantation (allo-HCT). The Kitlo HSC subset is enriched for multipotential precursors, but their T cell potential remains poorly characterized. Using a preclinical allo-HCT mouse model, we demonstrate that Kitlo HSCs provide superior thymic recovery and T cell reconstitution, resulting in improved immune responses to post-transplant infection. Kitlo HSCs with augmented bone marrow (BM) lymphopoiesis mitigate age-associated thymic alterations and enhance T cell recovery in middle-aged mice. Mechanistically, chromatin profiling reveals Kitlo HSCs exhibiting higher activity of lymphoid-specifying transcription factors, such as, ZBTB1. Zbtb1 deletion diminishes HSC engraftment and T cell potential; by contrast, reinstating Zbtb1 in megakaryocytic-biased Kithi HSCs rescues hematopoietic engraftment and T cell potential in vitro and in vivo. Furthermore, age-associated decline in Kitlo HSCs is associated with diminished T lymphopoietic potential in aged BM precursors; meanwhile, Kitlo HSCs in aged mice maintain enhanced lymphoid potential, but their per-cell capacity is diminished. Lastly, we observe an analogous human BM KITlo HSC subset with enhanced lymphoid potential. Our results thus uncover an age-related epigenetic regulation of lymphoid-competent Kitlo HSCs for T cell reconstitution.

22 October 2026 in Blood
Verified
Journal Article
Closed access
SMSham Mailankody
Sham Mailankody
SMSneha Mitra
Sneha Mitra
KHKevin Herrera
Kevin Herrera
BZBachisio Ziccheddu
Bachisio Ziccheddu
BCBriana Cadzin
Briana Cadzin
KPKarlo Perica
Karlo Perica
B-cell maturation antigen (BCMA)– and G protein–coupled receptor class C group 5 member D (GPRC5D)–directed therapies have shown high efficacy in the treatment of relapsed or refractory multiple myeloma, with multiple new immune therapies now approved. Preclinical studies have shown that the expression of BCMA and GPRC5D is heterogeneous in malignant plasma cells. We conducted a phase 1 dose-escalation trial of the BCMA chimeric antigen receptor (CAR) T-cell therapy MCARH125 alone or in combination with the GPRC5D CAR T-cell therapy MCARH109 in patients with relapsed or refractory multiple myeloma. Patients were treated across 3 dose levels, with the primary objective of establishing the safety of concurrent infusion. We treated 15 patients across 3 dose levels, including 6 patients who received MCARH125 alone and 9 patients treated with the concurrent infusion of MCARH125 and MCARH109. One patient each with MCARH 125 alone and the coinfusion of MCARH125 and MCARH109 developed immune effector cell–associated hemophagocytic syndrome. There were no instances of grade ≥3 cytokine release syndrome or immune effector cell–associated neurologic syndrome. The overall response for coinfusion was 78%, with a median progression-free survival of 18.2 months. Correlative analysis suggests that antigen loss may be an important mechanism of resistance even with dual-antigen targeting, and we show, to our knowledge for the first time that expansion of 1 CAR population may limit expansion of the second population because patients treated with dual CARs had significantly less BCMA CAR expansion compared with patients treated with BCMA CAR alone, despite equivalent BCMA CAR T-cell doses at infusion. This trial was registered at www.clinicaltrials.gov as NCT05431608.

14 June 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSneha Mitra
Sneha Mitra
RMRohan Malik
Rohan Malik
WWWilfred Wong
Wilfred Wong
ARAfsana Rahman
Afsana Rahman
AHAlexander J. Hartemink
Alexander J. Hartemink
CLChristina S. Leslie
Christina S. Leslie
We present a novel gene-level regulatory model called SCARlink that predicts single-cell gene expression from single-cell chromatin accessibility within and flanking (+/-250kb) the genic loci by training on multiome (scRNA-seq and scATAC-seq co-assay) sequencing data. The approach uses regularized Poisson regression on tile-level accessibility data to jointly model all regulatory effects at a gene locus, avoiding the limitations of pairwise gene-peak correlations and dependence on a peak atlas. SCARlink significantly outperformed existing gene scoring methods for imputing gene expression from chromatin accessibility across across high-coverage multiome data sets while giving comparable to improved performance on low-coverage data sets. Shapley value analysis on trained models identified cell-type-specific gene enhancers that are validated by promoter capture Hi-C and are 8x-35x enriched in fine-mapped eQTLs and 22x-35x enriched in fine-mapped GWAS variants across 83 UK Biobank traits. We further show that SCARlink-predicted and observed gene expression vectors provide a robust way to compute a chromatin potential vector field to enable developmental trajectory analysis.

8 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
XHXiao Huang
Xiao Huang
DFDan Feng
Dan Feng
SMSneha Mitra
Sneha Mitra
EAEmma S. Andretta
Emma S. Andretta
NHNima B. Hooshdaran
Nima B. Hooshdaran
ARAlexander Y. Rudensky
Alexander Y. Rudensky
SUMMARY: Regulatory T (Treg) cells contribute to solid organ cancer progression, except in colorectal cancer (CRC) despite being abundantly present. Here, we demonstrate that two distinct tumoral IL-10⁺ and IL-10⁻ Treg cell subsets exert opposing functions by counteracting and promoting CRC tumor growth, respectively. The tumor restraining activity of IL-10⁺ Treg cells was mediated by their suppression of effector CD4 T cell production of IL-17, which directly stimulates CRC tumor cell proliferation. Consistently, IL-10⁻ Treg cells were more abundant in both mouse and human CRC tumors than in tumor-adjacent normal tissues, whereas IL-10 + Treg cells exhibited the opposite distribution. Furthermore, relative abundance of IL-10⁺ and IL-10⁻ Treg cells correlated with better and worse disease prognoses in human CRC, respectively. This functional dichotomy between Treg cell subsets provides a rationale for therapeutic strategies to selectively target pro-tumoral Treg cells while preserving their anti-tumoral counterparts across barrier tissue cancers that harbor both subsets.